

Haematologica
HAEMATOL/2017/170480
Version 3

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Unal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, and Véronique Leblond

Disclosures: Employment: AB (F. Hoffmann-La Roche Ltd), KK (Roche Pharma AG, Germany), DM (F. Hoffmann-La Roche Ltd), and SO (F. Hoffmann-La Roche Ltd); leadership: AB (F. Hoffmann-La Roche Ltd); stock or other ownership: TW (Docrates Cancer Center, Finland), AB (F. Hoffmann-La Roche Ltd), and KK (F. Hoffmann-La Roche Ltd); honoraria: WH (Roche AG), KL (Amgen and Novartis), AS (F. Hoffmann-La Roche Ltd, Gilead, Janssen, Pharmacyclics, Novartis, and GSK), KK (F. Hoffmann-La Roche Ltd), and VL (Roche); consulting or advisory role: WH (Roche AG), JR (Jansen-Cilag, F. Hoffmann-La Roche Ltd, and Gilead), AS (F. Hoffmann-La Roche Ltd, Gilead, Janssen, Pharmacyclics, Novartis, and GSK), and VL (Roche); speakers' bureau: WH (Roche AG) and VL (Roche); research funding: WH (Roche AG) and KL (Roche, Hospira, Janssen-Cilag, TEVA, Mundipharma, and Novartis); expert testimony: TW (Novartis Finland Oy and Gilead Sciences Finland Oy); and travel, accommodations, and expenses: TW (Novartis Finland Oy, Gilead Sciences Finland Oy, and Roche), AB (F. Hoffmann-La Roche Ltd), KK (F. Hoffmann-La Roche Ltd), SO (F. Hoffmann-La Roche Ltd), and VL (Roche).

Contributions: WH and AB conceived and designed the study; MA, OI, PJ, KL, BA, CM, JR, AS, AU, TW, AB, DM, and VL collected and assembled the data; A-SM, WH, OI, KL, AS, AB, KK, SO, and VL analyzed and interpreted the data; AS and TW provided study materials and patients; and all authors wrote and approved the final version of the manuscript.